Why Catalyst Biosciences Shares Are Skyrocketing Today

Catalyst Biosciences Inc CBIO shares are trading higher by 180.26% at $1.06 after the company announced it sold its complement portfolio for $60 million.

A definitive asset purchase and sale agreement with Vertex Pharmaceuticals Incorporated VRTX has allowed Vertex to acquire Catalyst's portfolio of protease medicines that regulate complement, including CB 2782-PEG, for $60 million in cash.

See Also: Why Inovio Pharmaceuticals Stock Is Rising Today

Catalyst Biosciences is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions for individuals.

According to data from Benzinga Pro, Catalyst Biosciences has a 52-week high of $5.20 and a 52-week low of $3.05.

Loading...
Loading...
VRTX Logo
VRTXVertex Pharmaceuticals Inc
$455.38-1.02%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
40.26
Growth
Not Available
Quality
7.21
Value
36.15
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Comments
Loading...